This site uses cookies to ensure the best viewing experience for our readers.
Teva-Linked Biotech Company 89Bio Files for Nasdaq IPO

Teva-Linked Biotech Company 89Bio Files for Nasdaq IPO

Israel and San Francisco-based 89Bio raised a $60 million series A in October 2018

CTech  :  2019-10-15T12:26:24..

89Bio Ltd., a company created in 2018 by former Teva Pharmaceutical Industries Ltd. executives and based on biologic and small molecule drug candidates acquired from Teva, has filed on Friday for a Nasdaq initial public offering under the ticker ETNB. The company is looking to raise as much as $70 million with BofA Securities Inc., SVB Leerink LLC, RBC Capital Markets LLC, and Oppenheimer & Co. Inc. as the underwriters, according to a U.S. Securities and Exchange Commission (SEC) filing.

Based in central Israeli city Herzliya and in San Francisco, clinical-stage 89Bio develops treatments for liver and metabolic disorders. The company raised a $60 million series A in October 2018, led by New York-based healthcare investment firm OrbiMed Advisors LLC and its Israeli venture arm, which founded 89Bio, and Menlo Park-based Longitude Capital Management Co.

Nasdaq. Photo: Shutterstock Nasdaq. Photo: Shutterstock Nasdaq. Photo: Shutterstock

89Bio intends to use the IPO proceeds for clinical development, manufacturing and scaling up its operations, and general corporate purposes.

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS